Generic Name and Formulations:
Fluticasone propionate 0.05%; lotion.
Indications for CUTIVATE:
Adults and Children:
<1yr: not established. ≥1yr: apply a thin film to affected areas once daily for up to max 4 weeks; discontinue when control is achieved. Do not occlude.
Avoid use near eyes, on face, groin, or axillae. Do not use for diaper dermatitis, rosacea, perioral dermatitis, or on pre-existing skin atrophy. Avoid tight-fitting diapers or plastic pants. Risk of HPA axis suppression with high-potency steroids, prolonged use, application to large surface area, use of occlusive dressings, altered skin barrier, liver failure, young age; discontinue gradually, or reduce dose or potency if occurs. Treat infection if present; discontinue if infection persists or worsens. Lotion: avoid excessive sun exposure. Reevaluate periodically. Pregnancy (Cat.C). Nursing mothers.
Burning, stinging, pruritus, irritation, folliculitis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infections, skin atrophy, striae, miliaria, erythema, dry skin, excoriation; HPA axis suppression (esp. in children).
Crm, oint—contact supplier; Lotion—120mL
Sign Up for Free e-newsletters
Infectious Disease Advisor Articles
- Improving the Care of Aging Adults Living With HIV
- Infection Prevention Differs Between Small, Large Hospitals
- International Antiviral Society-USA Updates Recommendations for HIV Treatment and Prevention
- Previous Missed Appointments Predict Likelihood of Trend in Patients With HIV
- FDA Warns Against Long-Term Azithromycin Use for Some
- Identifying the Source of C difficile in Hospitalized Patients
- Antibiotics Often Unnecessary for Sacral Pressure Ulcers Complicated by Osteomyelitis
- Sensitivity and Specificity of 7 Treponemal Tests for Syphilis Diagnosis
- Automated EHR Algorithm More Effective Than Nurse-Driven Protocol for HCV, HIV Screening
- A Pan-Tuberculosis Regimen: The Debate Continues
- HCV Eradication in HIV/HCV-Coinfection Decreases Immune Activation
- Tolerability of Switching to Long-acting Cabotegravir Plus Rilpivirine From Current HIV-1 Regimen
- Time to Blood Culture Positivity Predictive of Mortality in S Aureus Infective Endocarditis
- C difficile Tied to Increased Graft Loss in Solid Organ Recipients
- Neurodevelopmental Anomalies, Birth Defects Linked to Zika ID'd